Breakthrough Development Could Further Lead to a Preventative For Type 2 Diabetes

For Immediate Release

ORLANDO, Fla./EWORLDWIRE/June 24, 2008 --- Response Scientific Inc. (RSI) today announced that its Receptor Biotech Division has developed a patented new prescription medication candidate that sensitizes the body's insulin receptors to perform more efficiently, thereby requiring less insulin to maintain healthy blood glucose levels.

The discovery, code-named INS2, has demonstrated the ability to dramatically reduce the amount of insulin required by insulin-dependent people with Type 2 Diabetes by as much as 50 percent. This efficacy presents itself in a matter of a few days, increasing its effectiveness steadily over one to two weeks to reach peak levels. "This is a promising day for anyone living with diabetes; the results of this discovery could change the lives of millions of people around the world," said Gregg Webster, RSI president and CEO. Our company is dedicated to the healthcare of people with insulin-sensitivity issues including diabetes, Polycystic Ovarian Syndrome (PCOS), and Alzheimer's disease."

In addition, INS2 may reduce the amount of the sulfonylurea class of drugs currently used for Type 2 Diabetes treatment. These drugs, i.e. Diabinese, Diabeta, Glucotrol and Amaryl cause the pancreatic beta cells to produce more and more insulin. While this is beneficial in lowering blood glucose levels, it may lead to a condition known as hyperinsulinemia that can result in low blood sugar (Hypoglycemia).

There are distinct problems associated with increased amounts of insulin in the body, not the least of which is weight gain*. Insulin is a polypeptide anabolic hormone that influences the metabolic synthesis of micro molecules, i.e. the lipids (cholesterol and triglycerides). The connection between cardiovascular events and these lipids is well known.

"The action we have discovered opens the door to both the development of a revolutionary medication, and it could lead to a preventive treatment for the 40 million Americans diagnosed with pre-diabetes or Metabolic Syndrome that are at high risk for developing full-blown Type 2 Diabetes," said Webster.

The company has formed a search committee to locate an appropriate site for its new headquarters and laboratory for the production of INS2 for an upcoming placebo controlled, double-blind clinical trial scheduled for a major American University Medical School.

*Diabetes Control and Complications Trial (DCCT) published in Diabetes Care in 1988, et al.

About Response Scientific Inc. ('http://www.responsescientific.com')

Response Scientific is currently a privately held company committed to the research and delivery of innovative healthcare products that enable people to live longer, healthier and more active lives. The company's focus is on disease states resulting from poor insulin sensitivity that includes Diabetes, PCOS, and Alzheimer's disease.

Contact:
Gregg Webster
407-574-2426

HTML:   http://www.eworldwire.com/pressreleases/18670
PDF:   http://www.eworldwire.com/pdf/18670.pdf
MOBILE:    http://e4mobile.com/view_release.php?id=18670
ONLINE NEWSROOM:   http://www.eworldwire.com/newsroom/313903.htm
NEWSROOM RSS FEED:   http://newsroom.eworldwire.com/xml/newsrooms/313903.xml
LOGO:   http://www.eworldwire.com/newsroom/313903.htm

CONTACT:
Gregg Webster
Response Scientific, Inc.
1800 Pembrook Drive
Orlando, FL 32810
PHONE. 407-574-2426

SOURCE: Response Scientific, Inc.